Beneficial effects of alkaline phosphatase in septic shock

Objective:Alkaline phosphatase may decrease the harmful effects of lipopolysaccharide by detoxifying lipid A. The aim of this study was to investigate whether administration of alkaline phosphatase is beneficial in a clinically relevant septic shock model. Design:Interventional laboratory study. Setting:University hospital animal research laboratory. Subjects:Fourteen fasted, anesthetized, invasively monitored, mechanically ventilated, female sheep (27.6 ± 3.9 kg). Interventions:Each animal received 1.5 g/kg body weight of feces intraperitoneally to induce sepsis. Ringer's lactate and a 6% hydroxyethyl starch solution were infused throughout the experiment to prevent hypovolemia. Two hours after feces injection, animals were randomized to alkaline phosphatase (60 units/kg intravenous bolus followed by a continuous infusion of 20 units/kg/hr for a total of 15 hrs) or no alkaline phosphatase (control group). Measurements and Main Results:All animals were studied until their spontaneous death or for a maximum of 30 hrs. Plasma alkaline phosphatase concentrations decreased in the control group but increased in the treatment group following alkaline phosphatase administration. In the treatment group, the Pao2/Fio2 ratio was higher (p < .05), blood interleukin-6 concentrations were lower (p < .05), and the survival time was longer (median time 23.8 vs. 17 .0 hrs, p < 0.05) than in the control group. There were no significant differences in systemic hemodynamics or diuresis. Conclusions:In this clinically relevant septic shock model, alkaline phosphatase administration improved gas exchange, decreased interleukin-6 concentrations, and prolonged survival time.

[1]  A. Esteban,et al.  Epidemiology of acute lung injury and acute respiratory distress syndrome , 2004, Seminars in respiratory and critical care medicine.

[2]  M. Boermeester,et al.  Bovine Intestinal Alkaline Phosphatase Attenuates the Inflammatory Response in Secondary Peritonitis in Mice , 2005, Infection and Immunity.

[3]  J. Vincent,et al.  FEVER CONTROL IN SEPTIC SHOCK: BENEFICIAL OR HARMFUL? , 2005, Shock.

[4]  H. Hirasawa,et al.  Sequential measurement of IL-6 blood levels in patients with systemic inflammatory response syndrome (SIRS)/sepsis. , 2005, Cytokine.

[5]  S. Young,et al.  Transcriptional Profiling of Lipopolysaccharide-Induced Acute Lung Injury , 2004, Infection and Immunity.

[6]  C. Bai,et al.  The role of aquaporin-1 (AQP1) expression in a murine model of lipopolysaccharide-induced acute lung injury , 2004, Respiratory Physiology & Neurobiology.

[7]  D. Meijer,et al.  PROTECTION AGAINST AN ESCHERICHIA COLI-INDUCED SEPSIS BY ALKALINE PHOSPHATASE IN MICE , 2004, Shock.

[8]  J. Vincent,et al.  USE OF LOW TIDAL VOLUME IN SEPTIC SHOCK MAY DECREASE SEVERITY OF SUBSEQUENT ACUTE LUNG INJURY , 2004, Shock.

[9]  W. Seinen,et al.  Calf Intestinal Alkaline Phosphatase, a Novel Therapeutic Drug for Lipopolysaccharide (LPS)-Mediated Diseases, Attenuates LPS Toxicity in Mice and Piglets , 2003, Journal of Pharmacology and Experimental Therapeutics.

[10]  J. Vincent,et al.  Low-dose vasopressin in the treatment of septic shock in sheep. , 2003, American journal of respiratory and critical care medicine.

[11]  P. Schmucker,et al.  Tissue metabolism during endotoxin shock after pretreatment with monophosphoryl lipid A. , 2003, Cardiovascular research.

[12]  H. Baelde,et al.  Induction of glomerular alkaline phosphatase after challenge with lipopolysaccharide , 2003, International journal of experimental pathology.

[13]  D. Meijer,et al.  Removal of Phosphate from Lipid A as a Strategy to Detoxify Lipopolysaccharide , 2002, Shock.

[14]  T. Matsunaga,et al.  Alkaline phosphatases reduce toxicity of lipopolysaccharides in vivo and in vitro through dephosphorylation. , 2002, Clinical Biochemistry.

[15]  J. Siddiqui,et al.  Six at Six: Interleukin-6 Measured 6 H After the Initiation of Sepsis Predicts Mortality Over 3 Days , 2002, Shock.

[16]  J. Vekemans,et al.  Monophosphoryl Lipid A Activates Both Human Dendritic Cells and T Cells1 , 2002, The Journal of Immunology.

[17]  B. Echtenacher,et al.  Differences in Innate Defense Mechanisms in Endotoxemia and Polymicrobial Septic Peritonitis , 2001, Infection and Immunity.

[18]  I. Koyama,et al.  Identification of pulmonary surfactant that bears intestinal-type and tissue-nonspecific-type alkaline phosphatase in endotoxin-induced rat bronchoalveolar fluid , 2001, Cell and Tissue Research.

[19]  M. Moser,et al.  The adjuvant monophosphoryl lipid A increases the function of antigen-presenting cells. , 2000, International immunology.

[20]  J. Millán,et al.  Alkaline Phosphatase Knock‐Out Mice Recapitulate the Metabolic and Skeletal Defects of Infantile Hypophosphatasia , 1999, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  S. Opal,et al.  Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. , 1999, The Journal of infectious diseases.

[22]  D. Papanicolaou,et al.  The Pathophysiologic Roles of Interleukin-6 in Human Disease , 1998, Annals of Internal Medicine.

[23]  D. Meijer,et al.  Dephosphorylation of endotoxin by alkaline phosphatase in vivo. , 1997, The American journal of pathology.

[24]  E. Vitetta,et al.  Vascular leak syndrome: a side effect of immunotherapy. , 1997, Immunopharmacology.

[25]  D. Meijer,et al.  A physiologic function for alkaline phosphatase: endotoxin detoxification. , 1997, Laboratory investigation; a journal of technical methods and pathology.

[26]  G. Gross,et al.  Monophosphoryl lipid A protects against endotoxic shock via inhibiting neutrophil infiltration and preventing disseminated intravascular coagulation. , 1994, Circulatory shock.

[27]  Rudbach Ja,et al.  Prophylactic use of monophosphoryl lipid A in patients at risk for sepsis. , 1994 .

[28]  R. Bone,et al.  Plasma Cytokine and Endotoxin Levels Correlate with Survival in Patients with the Sepsis Syndrome , 1993, Annals of Internal Medicine.

[29]  Corriveau Cc,et al.  Endotoxin as a therapeutic target in septic shock. , 1993 .

[30]  R. Danner,et al.  Endotoxin as a therapeutic target in septic shock. , 1993, Infectious agents and disease.

[31]  D. Herndon,et al.  Endotoxin (LPS) increases mesenteric vascular resistance (MVR) and bacterial translocation (BT). , 1990, The Journal of trauma.

[32]  E. Deitch,et al.  The role of intestinal barrier failure and bacterial translocation in the development of systemic infection and multiple organ failure. , 1990, Archives of surgery.

[33]  A. López,et al.  Injury versus inflammatory response in the lungs of rats intratracheally inoculated with bacterial lipopolysaccharide. , 1986, American journal of veterinary research.